Quantum BioPharma's Lucid-MS enters phase 2 trials to halt multiple sclerosis progression. Learn how this novel therapy targets myelin repair, offering hope for
2026/06/24
Quantum BioPharma advances Lucid-MS, a first-in-class drug for multiple sclerosis that protects myelin. Phase 2 trial preparation underway after successful safety
Tesla (NASDAQ:TSLA) stock is having a difficult session, falling 5% to $383 even as other electric vehicle (EV) names are showing far more resilience. Meanwhile
Quantum BioPharma (QNTM) advances Lucid-MS, a first-in-class MS therapy targeting myelin repair, into Phase 2 trials. Learn how this innovative approach could transform
2026/06/23
Lucid (LCID) stock declined 3.6% after announcing 18% workforce cuts, COO exit, and suspended 2026 production guidance in second layoff round this year. The post
TLDR Lucid is cutting ~18% of its U.S. workforce, covering full-time employees, contractors, and hourly production workers The cuts are expected to save approximately
Quantum BioPharma (NASDAQ: QNTM) advances Lucid-MS, a first-in-class neuroprotective drug for multiple sclerosis, entering Phase 2 trials after promising preclinical
2026/06/22
Quantum BioPharma's Lucid-MS, a patented drug candidate targeting myelin repair, enters phase 2 trials for MS. Learn how this novel approach could halt disease
Lucid CEO expects the partnership with Uber to fuel growth
2026/06/20
Microsoft Threat Intelligence has issued a warning to Windows users about a cryptocurrency clipper malware strain that spreads through USB drives and has been active
2026/06/19